Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.62 |
| ▸ | IKZF2 | Q9UKS7 | 6/20 | 0.59 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046061 | 1.00 | CRBN (1.00) | CRBNCSNK1A1IKZF2GSPT1CYP2C19 | |
| SCHEMBL27309803 | 1.00 | CRBN (1.00) | CRBNCSNK1A1IKZF2GSPT1CYP2C19 | |
| SCHEMBL34466336 | 1.00 | CRBN (1.00) | CRBNCSNK1A1IKZF2GSPT1CYP2C19 | |
| SCHEMBL29439976 | 0.90 | CRBN (1.00) | CRBN | |
| SCHEMBL21760366 | 0.90 | CRBN (1.00) | CRBN | |
| SCHEMBL21464551 | 0.89 | CRBN (0.80) | CRBNCSNK1A1IKZF2GSPT1DDB1 | |
| SCHEMBL25087702 | 0.88 | CRBN (0.78) | CRBNCSNK1A1IKZF2GSPT1CYP2C19 | |
| SCHEMBL20765391 | 0.86 | CRBN (0.75) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL29482963 | 0.86 | CRBN (0.75) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL31357772 | 0.85 | CRBN (0.74) | CRBNCSNK1A1IKZF2DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025073251-A1 | COMPOUND CAPABLE OF DEGRADING EPIDERMAL GROWTH FACTOR RECEPTOR, AND USE THEREOF | 普美瑞(苏州)生物科技有限公司 | 2025-04-10 | — | — | WO | disclosed |
| EP-4337259-A1 | COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF | Aprinoia Therapeutics Limited (HK) | 2024-03-20 | — | — | EP | disclosed |
| CN-117377496-A | Compounds for degrading alpha-synuclein aggregates and uses thereof | 新旭生技股份有限公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-4240743-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics, Incorporated (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022238737-A1 | COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2022-11-17 | — | — | WO | disclosed |
| EP-4058065-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | Aprinoia Therapeutics Limited (HK) | 2022-09-21 | — | — | EP | disclosed |
| CN-114728071-A | Compound for degrading TAU protein aggregate and application thereof | 新旭生技股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022099117-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-05-12 | — | — | WO | disclosed |